Hypogonadism, Male
46
9
11
24
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Published Results
12 trials with published results (26%)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
6.5%
3 terminated out of 46 trials
88.9%
+2.4% vs benchmark
41%
19 trials in Phase 3/4
50%
12 of 24 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 24 completed trials
Clinical Trials (46)
Testosterone Treatment in Men With Chronic Kidney Disease
Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone
Pain Alleviation With Testosterone in Opioid-Induced Hypogonadism
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
Testosterone Replacement Therapy in Hypogonadal Patients With Prostate Cancer Under Active Surveillance
52 Week Study + 24-Month Long-Term Extension of Safety, PK, & Efficacy of XYOSTED® for Testosterone Replacement in Male Adolescents With Hypogonadism
EndoPAT Device for Endothelial Dysfunction in ED
Ambulatory Blood Pressure Monitoring (ABPM) Study in Hypogonadal Men
TRT as an Adjunctive ERAS Therapy in ESRD Patients Undergoing Kidney Transplantation
Late Subclinical Cardiovascular Disease in Testicular Cancer Survivors
Natesto Spermatogenesis Reboot
Fertility Enhancement Through Regenerative Treatment in Ovaries and Testes
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
Salivary Testosterone in Men: Diurnal Variation and Post-Prandial Responses
Calciotropic Effects After HCG Stimulation Test
Vogelxo(R) ABPM Study in Hypogandal Men
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Ambulatory Blood Pressure Monitoring (ABPM) Extension Study of Oral Testosterone Undecanoate in Hypogonadal Men
The Effects of Natesto For Treatment Of Hypogonadism
Single-Dose Pharmacokinetics of Oral Testosterone Undecanoate With and Without Concomitant Inhibition of UGT2B17